Osteoporosis, Arthritis and Musculoskeletal Disorders

Treatment and Prevention of Osteoporosis during COVID-19

Over the last several months, an unique Coronavirus (COVID-19) pandemic has been reported in 219 nations, regions, or territories throughout the world, posing major health risks. The incubation time for viruses ranges from 2 to 14 days. Patients with osteoporosis have been found to be at a higher risk of developing COVID-19-related complications. Osteoporosis is a long-term disease that weakens bones and raises the risk of fracture. To limit the risk of future bone loss, structural integrity deterioration, and fractures, osteoporosis usually need long-term treatment. The identification of persistent osteoporosis issues should not be an unwelcome victim of the COVID-19 epidemic. In COVID-19 infected people, metabolic bone disease can cause difficulties. COVID-19 infected individuals are being treated by orthopaedic doctors who have been reassigned to other facilities. As a result, mandatory training for orthopaedics is required to grasp the signs of this illness. In a hospital setting with limited medical personnel and operating facilities, orthopaedic surgery and trauma surgery are difficult to perform. Clinicians must address the challenges posed by the crisis and explore how to continue to assist patients with chronic conditions in reducing morbidity and death